Skip To Main Content
Bart H. Steiner on Muck Rack

Bart H. Steiner

As seen in: British Journal of Cancer, The Journal of Allergy & Clinical Immunology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bart H.

Contact Bart H., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Dose-Dependent Suppression of Cytokine production from T cells by a Novel Phosphoinositide 3-Kinase Delta Inhibitor

|
By Giraldina Trevejo-Nunez, Lawrence P Kane, Bart H. Steiner, Emily Way Verified
| British Journal of Cancer Verified
It has been established by others that inhibition of PI3Kδ results in suppression of Th17 cell differentiation and function and can alleviate inflammation in human and animal models24,25,26,27. We analyzed the ability of a selective PI3Kδ inhibitor, Compound A, to inhibit IL-17 production from Th17 cells in vitro. Biochemical potency of Compound A (referred as Compound 18 by Patel et al.) is 0.4 nM, and selectivity is 200x or better against the other 3 isoforms28.
Open in Who Shared Issue with article?

Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis

|
By Gilead Sciences, Friedrich Horak, Kamal D. Puri, Bart H. Steiner
| The Journal of Allergy & Clinical Immunology Verified
To view the full text, please login as a subscribed user or purchase a subscription . Click here to view the full text on ScienceDirect. Phosphatidylinositol 3-kinase p110δ isoform (PI3K p110δ) activity is essential for mast cell activation, suggesting that inhibition of PI3K p110δ might be useful in treating allergic diseases. We sought to determine the effect of the PI3K p110δ–selective inhibitor idelalisib on allergic responses.
Open in Who Shared Issue with article?
See all 2 articles